The present invention relates to for treating illness, the especially nucleic acid construct and gene therapy vector comprising ATP7B variants of Wilson disease as caused by copper transhipment ATPase2 shortages or dysfunction. The AAV carriers designed according to the present invention significantly reduce urine Cu discharges and liver Cu contents in the Wilson disease mouse of the vehicle treated, while significant recovery ceruloplasmin activity. On the other hand, applying the carrier leads to serum aminotransferase levels at commencement and liver histological normalization, while being substantially reduced inflammatory infiltration.
